A case of celiac disease carrying the half DQ2 variant with a variety of psychiatric manifestations Authors: Akiko Sato, Yasuto Kunii, Takuya Tsunoda, Yoshiko Yamaguchi, Koichi Osonoe, Shuzo Hoshino Published: 2025 ABSTRACT AbstractBackgroundCeliac disease (CD) is an autoimmune‐mediated systemic disorder triggered by the ingestion of gluten. While it typically presents with gastrointestinal symptoms, it is also associated with various neuropsychiatric manifestations, including depression, migraine, developmental disorders, and epilepsy. In Asia, particularly in Japan, CD remains underdiagnosed, potentially delaying appropriate diagnosis and treatment for early intervention.Case PresentationWe report the case of a 16‐year‐old girl who presented with long‐standing behavioral issues, including repeated theft and rule violations since elementary school. She was diagnosed with attention‐deficit/hyperactivity disorder (ADHD), conduct disorder, and oppositional defiant disorder, but responded poorly to psychiatric treatment. In light of her coexisting physical symptoms, including chronic gastrointestinal complaints and unexplained laboratory abnormalities, further evaluation, including a duodenal biopsy, was conducted. The diagnosis of CD was confirmed, and a gluten‐free diet was initiated. Following dietary intervention, both her psychiatric and physical symptoms improved significantly, and no recurrence was observed during follow‐up.ConclusionThis case highlights the importance of considering CD as a differential diagnosis in adolescents with treatment‐resistant psychiatric symptoms, especially when accompanied by physical signs suggestive of systemic disease. Early recognition and intervention with a gluten‐free diet may improve both psychiatric and physical outcomes.Keywords: attention‐deficit/hyperactivity disorder (ADHD), celiac disease, conduct disorder, eating disorders, treatment‐resistant BACKGROUND Celiac disease (CD) is an autoimmune‐mediated systemic disorder induced by the ingestion of gluten. 1 , 2 In addition to intestinal symptoms such as diarrhea, appetite loss, weight loss, abdominal pain, lactose intolerance, abdominal bloating, and irritable bowel syndrome, CD may manifest with an extremely wide variety of extraintestinal symptoms, including dermatitis, cardiovascular symptoms associated with myocarditis, iron deficiency anemia, osteoporosis, and diverse neuropsychiatric symptoms. 3 In terms of neuropsychiatric symptoms, specifically, migraine, depression, developmental disorders such as attention‐deficit/hyperactivity disorder (ADHD) or autism spectrum disorder (ASD)‐related symptoms, and epilepsy have been pointed out to be associated with CD. 3 , 4 , 5 , 6 For the diagnosis of CD, characteristic symptoms including diarrhea and malabsorption as above, serological findings of CD antibody such as IgA anti‐tissue transglutaminase (IgA‐tTG) antibodies and IgA endomysial (IgA‐EMA) antibodies, demonstration of distinctive enteropathy on duodenal biopsy, clinical effectiveness of gluten‐free diet (GFD), and human leukocyte antigen (HLA) typing are essential to be considered together. Almost all patients with CD carry HLA‐DQ2 and/or DQ8 heterodimers, but the half DQ2 variant (HLA‐DQA1*0501/*0505) is extremely rare. 7 , 8 In this report, we show a case of CD carrying this rare variant with several psychiatric symptoms, such as conduct disorder, ADHD, and eating disorders such as anorexia nervosa. In Asia, especially in Japan, CD may still be underdiagnosed. Therefore, CD should be mentioned as a differential diagnosis in neurodevelopmental disorders accompanied by treatment‐resistant conduct disorder or eating disorder. Written informed consent was obtained from the patient for the presentation of this case report. At our institution, case reports do not require the approval of the Ethics Committee. CASE PRESENTATION This case involves a 16‐year‐old female who was referred to our outpatient psychiatric clinic due to persistent stealing behaviors observed both at home and at school since her early school years. She is the eldest of three siblings and has no history of perinatal complications or intellectual developmental delays. Comprehensive medical evaluations, including brain computed tomography (CT), electroencephalography (EEG), and laboratory investigations, revealed no significant physical abnormalities. Since infancy, she had multiple food allergies and was placed on an elimination diet that excluded wheat, although adherence to dietary restrictions was not consistently strict. From early childhood, she exhibited pronounced impulsivity and inattention, suggesting the presence of ADHD. From the early school years, she repeatedly engaged in stealing behavior, primarily involving food but extending to other items as well. Additionally, she demonstrated sexually inappropriate behavior, such as allowing boys to touch her body in exchange for money, and displayed intimidating behavior toward her younger siblings. These behaviors were considered indicative of conduct disorder. Although she did not exhibit distorted body image or an intense fear of gaining weight, she experienced recurrent episodes of binge eating and non‐intentional vomiting, resulting in significantly low body weight. Based on these clinical features, she was diagnosed with an unspecified feeding or eating disorder (Other Specified Feeding or Eating Disorder: OSFED). Pharmacological treatment with psychotropic medications—including atomoxetine, guanfacine, and aripiprazole—was attempted for ADHD and comorbid symptoms; however, the therapeutic response was limited, and clinical management remained challenging. Aripiprazole was used off‑label in this case. The rationale for its use was explained to the patient and her guardian, and informed consent was obtained. When she was 17 years old, she was admitted to our hospital for hypothermia and hyponatremia. During these hospital days, she underwent emergency surgery because she suddenly had a duodenal perforation, but the cause of this episode was unknown. Three months later, she was admitted to the Department of Psychiatry of our hospital for further examination because her behavioral disorders, such as repeated theft and varied physical symptoms, such as headaches, weight loss, and eczema, persisted. On admission, she had low body weight, hypotension, bradycardia, and eczema with pruritus on her entire body. We estimated some kind of organic disease in the background due to these varied symptoms, and since she exhibited a number of allergies since her infancy, we suspected the presence of CD. The diagnosis of CD is determined by characteristic histologic findings on duodenal biopsy and confirmation of clinical/histologic improvement with a GFD. In addition, most CD patients also showed an increased production of CD‐associated autoantibodies such as IgA‐tTG and IgA‐EMA. Moreover, specific allelic types in the HLA Class II genes, HLA‐DQA1 or HLA‐DQB1, must be existent for developing CD.5. Although both Anti IgA‐tTG and IgA‐EMA antibodies were negative in the present case, the duodenal endoscopic biopsy showed subtotal villous atrophy and partial increase in intraepithelial lymphocytes, and migration of leukocytes was observed (Figure 1). After starting and continuing the GFD, histologic resolution of the villous atrophy and a decrease in intraepithelial lymphocytes and leukocytes were observed (Figure 2). Her HLA type revealed half DQ2 variant (HLA‐DR11; DQA1*0505 with B1*0301). Then she was finally diagnosed with CD. After starting the GFD and continuing, her behavior and physical symptoms gradually improved in total, and no apparent symptoms have relapsed. Her body mass index, which was around 12 at admission, exceeded 20 at discharge after a GFD. In addition, her laboratory data showed abnormal levels of sodium and potassium, low body weight, low blood pressure, and stiff eczema also improved. Her own psychiatric symptoms also ameliorated, and she eventually stated, “I found that I felt better when I could empathize with other people.” Biopsy specimen of the duodenum before initiating a gluten‐free diet (hematoxylin and eosin staining). Endoscopic duodenal biopsy shows subtotal villous atrophy with increased intraepithelial lymphocytes and leukocyte infiltration. Biopsy specimen of the duodenum after adherence to a gluten‐free diet (hematoxylin and eosin staining). Histological improvement is observed, with restored villous architecture and reduced intraepithelial lymphocytes and leukocyte migration. DISCUSSION This case involved a female adolescent who presented with a combination of conduct disorder, ADHD, and disordered eating behaviors. Although she was initially diagnosed with an eating disorder and kleptomania and underwent psychiatric treatment, her clinical course was refractory and difficult to manage. The subsequent identification of unexplained hyponatremia, duodenal ulceration, and a history of allergic conditions since infancy prompted further investigation, leading to a diagnosis of CD. Remarkably, the initiation of a GFD resulted in significant improvement not only in her gastrointestinal and systemic symptoms but also in her psychiatric manifestations. This clinical course suggests that, in cases of treatment‐resistant psychiatric symptoms, particularly when accompanied by atypical somatic findings, the possibility of CD should be considered. Furthermore, this case underscores the importance of interdisciplinary evaluation and the potential reversibility of neuropsychiatric symptoms through targeted dietary intervention. This is the first case report of CD with a variety of psychiatric manifestations in Japan. Moreover, a case of CD carrying a half DQ2 heterodimer who elicited a variety of psychiatric issues is first depicted in the world. In Japan, there are only a few reports of CD itself, and few cases of this disease with psychiatric symptoms have been reported. However, multiple reports have been published internationally. 9 This patient was positive for one of the HLA‐DQ2 alleles, with an estimated genetic risk of approximately 0.05%. 8 In addition, the prevalence of CD in Japan is considerably lower than in Western countries. 10 This discrepancy is thought to be due to two main factors: the low frequency of HLA genotypes associated with CD susceptibility, and the relatively low intake of gluten‐containing foods in the Japanese population. In Western countries, approximately 99% of patients with CD possess at least one of the HLA‐DQ2 or HLA‐DQ8 haplotypes. Specifically, HLA‐DQ2 is present in about 90% of CD patients and in 20%–30% of appropriate control populations. In contrast, the frequency of HLA‐DQ2 among Japanese blood donors has been reported to be only 0.3%. The frequency of HLA‐DQ8, however, appears to be similar between Japanese and Caucasian populations, estimated at around 8%–11%. Because HLA‐DQ8 accounts for nearly all cases of CD that are not associated with DQ2, it is also considered a major genetic susceptibility factor. Another critical factor may be the intake of gluten, primarily from wheat and wheat‐based products. Among individuals who carry HLA‐DQ8, the adoption of Western dietary patterns may increase the risk of developing CD in the future. 11 , 12 These observations suggest a potential rise in the prevalence of CD in Japan in the coming years. Though there is no clear explanation of how an inflammatory process in the gastrointestinal tract affects the brain, it has become increasingly evident that close bidirectional interactions exist between these two organs, which are commonly called the gut–brain axis. 13 Neurological complications in CD represent a multifactorial and multilayered pathological process, initiated by an aberrant immune response to gluten. This process involves complex interactions among autoantibodies, alterations in the gut microbiota, microglial activation, and dysregulated microRNAs (miRNAs), ultimately affecting both the central and peripheral nervous systems. Notably, several studies have reported reductions in antibody titers and improvements in neurological symptoms following the implementation of a GFD, suggesting that early diagnosis and dietary intervention may have a significant impact on neurological outcomes in patients with CD. 14 Furthermore, existing studies have reported a 1.2‐ to 1.8‐fold higher incidence of psychological comorbidities and symptoms in children with CD compared to those without CD. 15 In the present case, the patient had been diagnosed with conduct disorder, ADHD, and an eating disorder. Notably, both ADHD and eating disorders have been reported to be associated with CD, 6 , 16 , 17 and conduct disorder has long been recognized as commonly comorbid with ADHD. 18 There are also reports, including the present case, in which psychiatric symptoms improved following the initiation of a GFD. 19 These findings suggest that screening for CD may be clinically useful in children with treatment‐resistant psychiatric disorders. In the present case, underweight and undernutrition associated with an unspecified feeding and eating disorder may have contributed to the exacerbation of ADHD‐like symptoms and conduct problems, possibly through impaired attention and executive function. Cognitive improvement following weight restoration has been reported in patients with anorexia nervosa, 20 and there is growing evidence that malnutrition negatively affects cognitive and behavioral development. 21 Accordingly, the improvement in nutritional status and body weight through the initiation of a GFD may have played a critical role in alleviating psychiatric symptoms, including those related to ADHD. Recent research has highlighted the significance of the microbiota–gut–brain axis in modulating key neurotransmitters such as serotonin, dopamine, and gamma‐aminobutyric acid (GABA), which are deeply involved in regulating mood, attention, and impulse control. Dysbiosis and intestinal inflammation associated with CD can impair neurotransmitter production and transport, potentially contributing to emotional dysregulation, inattention, and behavioral difficulties. GFD has been reported to reduce intestinal inflammation and may restore altered neurotransmitter pathways, which could explain the neuropsychiatric improvement observed in this case. 22 , 23 Furthermore, this patient experienced prolonged family discord, which may have contributed to the persistence of psychiatric symptoms, including conduct problems, and lowered self‐esteem and self‐efficacy. To address these psychosocial aspects, we introduced therapeutic interventions including bibliotherapy and therapeutic letter‐writing. These approaches aimed to enhance emotional expression, strengthen self‐awareness, and facilitate the restoration of family relationships. Post‐treatment psychological assessments revealed slight improvements in impulsivity, heightened sensitivity to others' behavior, and increased awareness of emotional fluctuations. Taken together, these multidimensional interventions—nutritional, neurobiological, and psychosocial—may have synergistically contributed to the patient's overall recovery. CONCLUSION As shown in this case, the diagnosis of CD is predicted to improve the prognosis of patients. Therefore, CD should be mentioned as a differential diagnosis in neurodevelopmental disorders accompanied by treatment‐resistant conduct disorder or eating disorder. AUTHOR CONTRIBUTIONS Akiko Sato, Koichi Osonoe, and Shuzo Hoshino treated the patient. Takuya Tsunoda did the duodenal endoscopic biopsy. Yoshiko Yamaguchi did the pathological examination. Akiko Sato, Yasuto Kunii, Koichi Osonoe, and Shuzo Hoshino obtained the data and drafted the manuscript. CONFLICT OF INTEREST STATEMENT The authors declare no conflicts of interest. ETHICS APPROVAL STATEMENT N/A. PATIENT CONSENT STATEMENT Written consent for publication was obtained from the patient. CLINICAL TRIAL REGISTRATION N/A. ACKNOWLEDGMENTS The authors have nothing to report. Sato A, Kunii Y, Tsunoda T, Yamaguchi Y, Osonoe K, Hoshino S. A case of celiac disease carrying the half DQ2 variant with a variety of psychiatric manifestations. Psychiatry Clin Neurosci Rep. 2025;4:e70267. 10.1002/pcn5.70267 DATA AVAILABILITY STATEMENT The data that support the findings of this study are available from the corresponding author upon reasonable request. All data generated or analyzed during this study are included in this article. REFERENCES Associated Data Data Availability Statement The data that support the findings of this study are available from the corresponding author upon reasonable request. All data generated or analyzed during this study are included in this article.